SPRB — Spruce Biosciences Share News
0.000.00%
Last trade - 00:00Spruce Biosciences to wind down investment for genetic disorder drug (updated)
Spruce Biosciences to wind down investment for genetic disorder drug
Spruce Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary
Spruce Biosciences Inc expected to post a loss of 24 cents a share - Earnings Preview
Spruce Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Spruce Biosciences Inc expected to post a loss of 32 cents a share - Earnings Preview
Brief: Spruce Biosciences Inc On June 13, Co Entered Into A "Stalking Horse" Asset Purchase Agreement
Brief: Spruce Biosciences, HMNC To Initiate Phase 2 Study For Treatment Of MDD In Q4 2024
Brief: Spruce Biosciences Presents Phase 2 POWER Study Results Of Tildacerfont For Treatment Of Polycystic Ovary Syndrome
Spruce Biosciences Inc reports results for the quarter ended in January - Earnings Summary
Spruce Biosciences Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Dick's Sporting Goods, Build-A-Bear, Spruce Biosciences
Spruce Biosciences Inc reports results for the quarter ended in December - Earnings Summary
U.S. STOCKS ON THE MOVE-Netflix, RTX, Dollar General
Spruce Biosciences plummets as genetic disorder therapy fails mid-stage study
Spruce Bio slips as genetic disorder drug fails mid-stage study in adults
Brief: Spruce Biosciences' Tildacerfont Fails Cahmelia-203 Study In Adult Classic CAH
Spruce Biosciences Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Spruce Biosciences Completes Enrollment In Cahmelia-204 Study For Adult Classic Congenital Adrenal Hyperplasia